Clinical trial
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to…
NCT03215706 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT03215706 |
|---|---|
| Title | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC |
| Official title | A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer |
| Acronym | CheckMate 9LA |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | Ipilimumab, Nivolumab, Carboplatin, Paclitaxel, Pemetrexed, Cisplatin |
| Enrollment | 719 |
| Start date | Aug 24, 2017 |
| Primary completion | Aug 16, 2019 |
| Completion | Oct 18, 2024 |
| First posted | Jul 12, 2017 |
| Last update posted | Dec 17, 2025 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Italy, Japan and 7 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: